Micah J Savin1, Summer G Frank-Pearce2, Kim Pulvers3, Damon J Vidrine4. 1. HIV Neurobehavioral Research Center, Department of Psychiatry, University of California San Diego, 9500 Gilman Dr., San Diego, CA 92093, USA. Electronic address: msavin@fordham.edu. 2. HIV Neurobehavioral Research Center, Department of Psychiatry, University of California San Diego, 9500 Gilman Dr., San Diego, CA 92093, USA. Electronic address: SFRANK@ouhsc.edu. 3. HIV Neurobehavioral Research Center, Department of Psychiatry, University of California San Diego, 9500 Gilman Dr., San Diego, CA 92093, USA. Electronic address: kpulvers@csusm.edu. 4. HIV Neurobehavioral Research Center, Department of Psychiatry, University of California San Diego, 9500 Gilman Dr., San Diego, CA 92093, USA. Electronic address: Damon-Vidrine@ouhsc.edu.
Abstract
BACKGROUND: This secondary analysis aims to describe, over time, the relationship between HIV disease progression and intention to quit cigarette smoking among current monocigarette users with and without a lifetime history of polytobacco use. METHODS: Participants completed a baseline assessment at the time of HIV care initiation and four follow-up assessments (3, 6, 9, and 12-months). Assessments included biochemically verified smoking status and audio computer-assisted self-interviews assessing psychosocial, substance use, and clinical variables known to influence smoking behaviors. Using linear and generalized linear fixed-effects models, we modeled the covariance structure for the repeated outcome measures (intention to quit and 7-day point prevalence smoking abstinence) across the study time points and included a three-way interaction term to examine the effects of disease stage and tobacco product use. RESULTS: Participants (N = 357) were 73.1% male, 67.3% black/African American, and had a mean (SD) age of 38.7 (10.6) years. At baseline, lifetime polytobacco users reported significantly worse HIV-related symptoms and burdens, illness perception, social support, and nicotine dependence. Intention to quit, but not smoking abstinence, was predicted by a three-way interaction between time from HIV care initiation, disease progression, and tobacco product use (p = .04). Overall, progressive HIV was associated with greater intention to quit smoking cigarettes. However, the relationship differed over time between the two tobacco product groups. CONCLUSION: Future studies should consider tailoring the timing of cessation interventions upon disease stage and lifetime history of polytobacco use.
BACKGROUND: This secondary analysis aims to describe, over time, the relationship between HIV disease progression and intention to quit cigarette smoking among current monocigarette users with and without a lifetime history of polytobacco use. METHODS:Participants completed a baseline assessment at the time of HIV care initiation and four follow-up assessments (3, 6, 9, and 12-months). Assessments included biochemically verified smoking status and audio computer-assisted self-interviews assessing psychosocial, substance use, and clinical variables known to influence smoking behaviors. Using linear and generalized linear fixed-effects models, we modeled the covariance structure for the repeated outcome measures (intention to quit and 7-day point prevalence smoking abstinence) across the study time points and included a three-way interaction term to examine the effects of disease stage and tobacco product use. RESULTS:Participants (N = 357) were 73.1% male, 67.3% black/African American, and had a mean (SD) age of 38.7 (10.6) years. At baseline, lifetime polytobacco users reported significantly worse HIV-related symptoms and burdens, illness perception, social support, and nicotine dependence. Intention to quit, but not smoking abstinence, was predicted by a three-way interaction between time from HIV care initiation, disease progression, and tobacco product use (p = .04). Overall, progressive HIV was associated with greater intention to quit smoking cigarettes. However, the relationship differed over time between the two tobacco product groups. CONCLUSION: Future studies should consider tailoring the timing of cessation interventions upon disease stage and lifetime history of polytobacco use.
Authors: Jennifer O Lam; Tory Levine-Hall; Nicole Hood; Stacey E Alexeeff; Michael A Horberg; Kelly C Young-Wolff; Stacy A Sterling; Andrew Williams; Constance Weisner; Derek D Satre; Michael J Silverberg Journal: Drug Alcohol Depend Date: 2020-06-18 Impact factor: 4.852